Vascular BioSciences announces publication of “CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension” in the latest issue of The Open Respiratory Medicine (Volume 17, April 27, 2023) by Abraham Rothman, Humberto Restrepo, William N. Evans, Valeri Sarukhanov, and David Mann. This article details how the homing peptide CAR (CARSKNKDC) selectively enhances the acute vasodilatory effects of fasudil on the pulmonary vascular bed in a porcine model of pulmonary hypertension (PH).
Despite the approval of several medications for PH, morbidity and mortality remain high. Systemic hypotension by these drugs may limit the use of PH medications. Pharmacologically enhancing the selectivity of vasoactive drugs on the pulmonary vascular bed using CAR was demonstrated to be beneficial for enhancing the vasodilatory effect and reducing side effects. This study extends the benefits of CAR from a rodent model to a large animal model of acute and chronic pulmonary hypertension.
Dr. Abraham Rothman, M.D. of the Children’s Heart Center, Nevada and Professor of Medicine at the University of Nevada School of Medicine, states that “by selectively targeting the pulmonary vasculature, CAR uniquely offers the potential to decrease the doses and minimize the side effects of medications used to treat pulmonary hypertension in patients.”
Vascular BioSciences CEO and study co-author David Mann commented, “This study confirmed that the co-administration of CAR resulted in a safe, enhanced vasodilator profile of fasudil in the pulmonary vasculature of a large experimental model of acute and chronic pulmonary hypertension, leading us one step closer to clinical trials in humans.”
A copy of this article can be found here: https://openrespiratorymedicinejournal.com/VOLUME/17/ELOCATOR/e187430642303160/FULLTEXT/

About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides targeted solutions for serious diseases in order to enhance and prolong human life.

Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult-to-treat diseases.

More information about VBS is available at http://www.vascularbiosciences.com/
For more information, please contact [email protected]